Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $1.55 billion. The enterprise value is $1.71 billion.
| Market Cap | 1.55B |
| Enterprise Value | 1.71B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 182.32 million shares outstanding. The number of shares has increased by 10.29% in one year.
| Current Share Class | 182.32M |
| Shares Outstanding | 182.32M |
| Shares Change (YoY) | +10.29% |
| Shares Change (QoQ) | -2.71% |
| Owned by Insiders (%) | 3.50% |
| Owned by Institutions (%) | 59.82% |
| Float | 175.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 47.11 |
| PS Ratio | 4.61 |
| Forward PS | 3.58 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 27.77 |
| P/OCF Ratio | 27.31 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 35.14, with an EV/FCF ratio of 30.78.
| EV / Earnings | n/a |
| EV / Sales | 5.11 |
| EV / EBITDA | 35.14 |
| EV / EBIT | 46.83 |
| EV / FCF | 30.78 |
Financial Position
The company has a current ratio of 1.45
| Current Ratio | 1.45 |
| Quick Ratio | 0.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | 5.10 |
| Debt / FCF | 5.20 |
| Interest Coverage | 1.30 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 6.13% |
| Return on Invested Capital (ROIC) | 8.84% |
| Return on Capital Employed (ROCE) | 16.46% |
| Weighted Average Cost of Capital (WACC) | 8.74% |
| Revenue Per Employee | $771,067 |
| Profits Per Employee | -$39,460 |
| Employee Count | 435 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 0.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.13% in the last 52 weeks. The beta is 0.85, so XERS's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +6.13% |
| 50-Day Moving Average | 8.26 |
| 200-Day Moving Average | 7.02 |
| Relative Strength Index (RSI) | 51.55 |
| Average Volume (20 Days) | 1,689,205 |
Short Selling Information
The latest short interest is 8.73 million, so 4.79% of the outstanding shares have been sold short.
| Short Interest | 8.73M |
| Short Previous Month | 9.22M |
| Short % of Shares Out | 4.79% |
| Short % of Float | 4.96% |
| Short Ratio (days to cover) | 5.33 |
Income Statement
In the last 12 months, XERS had revenue of $335.41 million and -$17.17 million in losses. Loss per share was -$0.10.
| Revenue | 335.41M |
| Gross Profit | 290.39M |
| Operating Income | 36.59M |
| Pretax Income | -17.17M |
| Net Income | -17.17M |
| EBITDA | 48.77M |
| EBIT | 36.59M |
| Loss Per Share | -$0.10 |
Balance Sheet
The company has $121.75 million in cash and $289.44 million in debt, with a net cash position of -$167.70 million or -$0.92 per share.
| Cash & Cash Equivalents | 121.75M |
| Total Debt | 289.44M |
| Net Cash | -167.70M |
| Net Cash Per Share | -$0.92 |
| Equity (Book Value) | -9.73M |
| Book Value Per Share | -0.06 |
| Working Capital | 85.19M |
Cash Flow
In the last 12 months, operating cash flow was $56.61 million and capital expenditures -$938,000, giving a free cash flow of $55.67 million.
| Operating Cash Flow | 56.61M |
| Capital Expenditures | -938,000 |
| Depreciation & Amortization | 12.18M |
| Net Borrowing | n/a |
| Free Cash Flow | 55.67M |
| FCF Per Share | $0.31 |
Margins
Gross margin is 86.58%, with operating and profit margins of 10.91% and -5.12%.
| Gross Margin | 86.58% |
| Operating Margin | 10.91% |
| Pretax Margin | -5.12% |
| Profit Margin | -5.12% |
| EBITDA Margin | 14.54% |
| EBIT Margin | 10.91% |
| FCF Margin | 16.60% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.29% |
| Shareholder Yield | -10.29% |
| Earnings Yield | -1.11% |
| FCF Yield | 3.60% |
Analyst Forecast
The average price target for XERS is $11.71, which is 38.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.71 |
| Price Target Difference | 38.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 23.65% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XERS has an Altman Z-Score of 0.6 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.6 |
| Piotroski F-Score | 6 |